Frequency of reporting on patient and public involvement (PPI) in research studies published in a general medical journal : a descriptive study by Price, Amy et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Original citation:  
Price, Amy, Schroter, Sara, Snow, Rosamund, Hicks, Melissa, Harmston, 
Rebecca, Staniszewska, Sophie, Parker, Samand Richards, Tessa (2018) Frequency of 
reporting on patient and public involvement (PPI) in research studies published in a general 
medical journal : a descriptive study. BMJ Open, 8 (3). e020452. doi:10.1136/bmjopen-2017-
020452 
 Permanent WRAP URL: 
http://wrap.warwick.ac.uk/101535            
       
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work of researchers of the 
University of Warwick available open access under the following conditions. 
 
This article is made available under the Creative Commons Attribution-NonCommercial 4.0 
(CC BY-NC 4.0) license and may be reused according to the conditions of the license.  For 
more details see: http://creativecommons.org/licenses/by-nc/4.0/    
 
A note on versions: 
The version presented in WRAP is the published version, or, version of record, and may be 
cited as it appears here. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk 
 
1Price A, et al. BMJ Open 2018;8:e020452. doi:10.1136/bmjopen-2017-020452
Open Access 
Frequency of reporting on patient and 
public involvement (PPI) in research 
studies published in a general medical 
journal: a descriptive study
Amy Price,1,2 Sara Schroter,1 Rosamund Snow,3 Melissa Hicks,1 
Rebecca Harmston,1 Sophie Staniszewska,4 Sam Parker,1 Tessa Richards1
To cite: Price A, Schroter S, 
Snow R, et al.  Frequency 
of reporting on patient and 
public involvement (PPI) in 
research studies published in 
a general medical journal: a 
descriptive study. BMJ Open 
2018;8:e020452. doi:10.1136/
bmjopen-2017-020452
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2017- 
020452).
Dr. Snow died on 2 February 
2017.
Received 6 November 2017
Revised 21 February 2018
Accepted 26 February 2018
1The BMJ, London, UK
2Department for Continuing 
Education, The University of 
Oxford, Oxford, UK
3Health Experiences Institute, 
Nuffield Department of Primary 
Care Health Sciences, Medical 
Sciences Division, University of 
Oxford, Oxford, UK
4Warwick Medical School, 
University of Warwick, Coventry, 
UK
Correspondence to
Amy Price;  aprice@ bmj. com
Research
AbstrACt
Objectives While documented plans for patient and public 
involvement (PPI) in research are required in many grant 
applications, little is known about how frequently PPI 
occurs in practice. Low levels of reported PPI may mask 
actual activity due to limited PPI reporting requirements. 
This research analysed the frequency and types of 
reported PPI in the presence and absence of a journal 
requirement to include this information.
Design and setting A before and after comparison of 
PPI reported in research papers published in The BMJ 
before and 1 year after the introduction of a journal policy 
requiring authors to report if and how they involved 
patients and the public within their papers.
results Between 1 June 2013 and 31 May 2014, 
The BMJ published 189 research papers and 1 (0.5%) 
reported PPI activity. From 1 June 2015 to 31 May 2016, 
following the introduction of the policy, The BMJ published 
152 research papers of which 16 (11%) reported PPI 
activity. Patients contributed to grant applications in 
addition to designing studies through to coauthorship and 
participation in study dissemination. Patient contributors 
were often not fully acknowledged; 6 of 17 (35%) papers 
acknowledged their contributions and 2 (12%) included 
them as coauthors.
Conclusions Infrequent reporting of PPI activity does not 
appear to be purely due to a failure of documentation. 
Reporting of PPI activity increased after the introduction 
of The BMJ’s policy, but activity both before and after was 
low and reporting was inconsistent in quality. Journals, 
funders and research institutions should collaborate 
to move us from the current situation where PPI is an 
optional extra to one where PPI is fully embedded in 
practice throughout the research process.
bACkgrOunD 
Patient and public involvement (PPI) in 
research is defined as research actively carried 
out ‘with’ or ‘by’ members of the public rather 
than ‘to’, ‘about’ or ‘for’ them.1 In health 
research, the term public is interpreted 
broadly to include potential patients, carers, 
people who use health and social services, 
people or organisations that support users of 
health or social services and other interested 
members of the community. Terminology 
for PPI can be confusing and varies across 
cultures; terms can be used interchange-
ably. We consider PPI to be distinct from 
public engagement where research aware-
ness is raised, and knowledge is shared and 
nurtured through fostering conversations 
between clinicians and researchers and the 
public, patients and carers. PPI is also distinct 
from being a participant in a research study. 
In PPI, the public become active partners 
in one or multiple aspects of the research, 
including generating the research question, 
grant writing, study design, study conduct, 
analysis, evaluation, cowriting publications 
and their dissemination.2 Involving patients 
and the public in research can improve the 
quality, consistency, content, experience 
and value of health research to end users.2–4 
Studies involving patients as research part-
ners have shown improvements in study 
recruitment and participation5 6, in policy 
formulation7 and clinical relevance.8 9 PPI in 
strengths and limitations of this study
 ► Plans for patient and public involvement (PPI) in 
research are required by many funders and ethical 
review boards, but actual implementation of PPI in 
practice is an under-reported area.
 ► Low levels of reported PPI may mask actual PPI ac-
tivity due to limited reporting requirements. We de-
scribe reporting rates in the presence and absence 
of a journal requirement to report this information.
 ► We only sampled research published in one journal, 
but it was the change in The BMJ’s policy that en-
abled a before and after study.
 ► We cannot attribute causation to the implementation 
of this policy as the introduction of the policy itself 
may have attracted more research papers describ-
ing studies that included PPI.
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prioritising research questions may also reduce research 
‘waste’ by putting greater focus on addressing the ques-
tions that matter to patients.10 PPI also acts as a catalyst 
for researchers, the public and decision-makers to brain-
storm research problems and find solutions together.11–13 
For at least 15 years, ethical review boards and funders 
in the UK have been stipulating that members of the 
public be involved in research design and study conduct. 
They recommend lay members play an active role on 
research steering boards and in approval committees.14 
Practice varies by organisation and country. While there 
are minimal data on the effectiveness of these policies, 
the UK has seen an increase (from 67% in 2010 to 78% in 
2012) in the documentation of planned PPI in research 
applications submitted to the UK’s National Research 
Ethics Service (NRES).15 The extent to which PPI is 
embedded in research is an under-reported area and 
while a few studies have addressed this area, they were 
conducted some time ago and limited to the UK setting 
when the requirements to include patients and the public 
in research was relatively new. Hanley et al16 reported that 
one-third of 62 UK clinical trial coordinating centres 
surveyed had involved ‘consumers’ in the research they 
had conducted between 1990 and 1998. Barber et al17 
conducted a survey of 518 UK researchers with projects 
registered on the National Research Register (ie, projects 
funded by or of interest to the UK NHS) and due to be 
completed in 2002 and found 17% involved ‘consumers’. 
In 2002, Telford et al18 reported that one-third of NHS 
trusts in the region surveyed were actively involving 
‘consumers’ in the research process.
Reporting of PPI is hampered by inconsistent termi-
nology and little consensus on reporting methods.2 
Journals and peer reviewers do not usually request PPI 
information within manuscripts, so an absence of infor-
mation about PPI in research papers could be attribut-
able to either a lack of reporting or a lack of PPI activity. 
As part of its Patient Partnership Strategy, The BMJ, an 
influential international general medical journal, is 
actively promoting PPI in research,19 20 and in 2014 it 
introduced an innovative policy instructing submitting 
authors to report if and how they involved patients. 
Authors of research papers are required to include a PPI 
declaration in their Methods section under a subheading 
called Patient Involvement. This policy is intended to foster 
increased researcher/patient collaboration by shifting 
cultural expectations about the importance of conducting 
and reporting on PPI. Authors of all research paper 
submissions are required to state if and how patients 
were involved in developing the research question and 
outcome measures, designing and conducting the 
research, assessing the burden of the intervention (where 
applicable) and how the results will be disseminated to 
patients. Authors are also instructed to thank patients 
involved in the contributorship statement/acknowledg-
ments. Where authors have not involved patients, they 
are asked explicitly to report this in the paper. Papers 
describing studies without patient involvement are not 
rejected solely for this reason. At the point of article 
acceptance, editors check that information about PPI 
activity is recorded in the manuscript and request this 
declaration if it is absent.
We describe a comparison of published research papers 
in The BMJ before and after the introduction of its PPI 
policy to assess how researchers are involving patients 
and the public in research, whether the policy leads to an 
increase in reporting of PPI and whether infrequent docu-
mentation of PPI information in research is a reporting 
phenomenon or an absence of PPI activity.
MethODs
sampling
We identified two samples of research papers published 
in The BMJ. The first sample was original research papers 
published under the research section of the journal in 
the 12-month period between 1 June 2013 and 31 May 
2014, just before the introduction of new journal guid-
ance to submitting authors about the need to report if 
and how they involved patients in the research described. 
The second sample included research papers published 
under the research section of the journal in the 12-month 
period between 1 June 2015 and 31 May 2016, 1 year after 
The BMJ introduced its PPI reporting policy for submitted 
research papers.
Inclusion criteria
We included all research papers published in the two 
sampling periods. No study designs were excluded as 
PPI is considered possible with studies that have no 
direct contact with participants for example, systematic 
reviews.21–23
Process
Each research paper in the pre-implementation sample 
was read independently by two assessors, and all infor-
mation about how patients were involved in each stage 
of the research process was extracted. Footnotes and 
contributorship notes were also checked. For the post-im-
plementation sample, the new PPI section entitled Patient 
Involvement within the Methods section was read by two 
assessors, and if PPI activity was indicated assessors then 
read the whole paper and extracted all information about 
PPI wherever the details were reported. Data were also 
extracted from the Acknowledgments section and the 
Contributorship statement for all papers in the post-im-
plementation sample. For the few papers in the post-im-
plementation sample where a PPI section was not included 
within the manuscript, the information was checked and 
extracted in the same way as for the pre-implementation 
sample. Funding sources were extracted and classified as 
industry (commercial), trust (charities, trusts, founda-
tions), governmental (government research organisation 
funded by taxpayers or works commissioned and paid for 
by government) or none (no external funding received).
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Patient involvement
The study was instigated by RS (former Patient Editor, 
The BMJ) and SS. AP, RS, TR are/were patients with 
long-term medical conditions committed to the involve-
ment of patients in all stages of the research process and 
were involved in all phases of this study. Two BMJ patient 
reviewers, MH and RH, were involved with the interpreta-
tion of the results, editing and preparing the manuscript 
for publication and will be involved in the dissemination 
plan for the paper. All patient contributors meet the 
ICMJE criteria for authorship and as such we acknowl-
edge their valuable contributions through coauthorship 
of this manuscript. PPI enriched our understanding of 
patient involvement and contributed to the accuracy, 
readability and relevance of the paper.
results
Frequency of reporting
Between 1 June 2013 and 31 May 2014, The BMJ 
published 189 research papers of which 62 (33%) had a 
corresponding author based in the UK. Only one (0.5%) 
of the 189 included some information on PPI activity 
(table 1).24 
Between 1 June 2015 and 31 May 2016, following the 
introduction of the PPI policy, The BMJ published 152 
research papers of which 37 (24%) had a corresponding 
author based in the UK. A total of 130 (86%) of the 152 
papers included a PPI statement within the Methods 
section of the manuscript. Sixteen (11%) of the 152 
papers reported some PPI activity (table 2). This was a 
10-fold increase in the proportion of papers reporting 
PPI compared with pre-implementation, but still only a 
small proportion of the total number of papers published. 
Some papers included information in the Patient Involve-
ment section that did not describe PPI, and it was some-
times hard to distinguish qualitative data collection 
for example, capturing patient’s perspectives from active 
participation in the research process.
types of PPI reported
Table 3 shows a summary of PPI activity reported at each 
stage of the research process across the two sampling 
periods. As the pre-implementation sample only consisted 
of one article, it is not appropriate to compare the type of 
reporting between the two samples.
Pre-implementation sample
The Clinical effectiveness of collaborative care for depres-
sion in UK primary care (CADET) cluster randomised 
controlled trial (RCT) comparing the clinical effective-
ness of collaborative care with usual care in the manage-
ment of patients with moderate to severe depression in 
the UK primary care setting included a patient advocate 
as a coauthor on the byline of the paper.24 The contrib-
utorship statement implies that the patient was a full 
member of the research team and as such would have had 
the opportunity to contribute to multiple aspects of the 
research, yet it is difficult to extrapolate explicitly which 
aspects and phases of the research the patient advocate 
contributed to other than ‘writing and editing the manu-
script’. This case illustrates how in the absence of guid-
ance on how and what to report for PPI, activity may go 
unreported. Before conducting this trial, the team devel-
oped the collaborative care intervention and captured 
the patients’ perspective through in-depth qualitative 
interviews with patients. Their phase II testing of the 
intervention indicated that it was acceptable to patients. 
It was difficult to untangle whether this was active PPI 
or qualitative research eliciting the patient perspective. 
The rationale for including this as PPI was that testing 
the acceptability using participant feedback guided the 
course of the research.
Post-implementation sample
The sixteen studies included eight RCTs,25–32 five cohort 
studies,33–37 one population-based study,38 one real-
world effectiveness study39 and one systematic review 
and meta-analysis40 (table 2). Eleven of these 16 studies 
had a corresponding author based in the UK, one in the 
USA, two in the Netherlands, one in Mexico and one in 
Sweden. Patients were involved from the earliest stages 
of study design in grant applications or contributing to 
study protocols (19%), helping to set the research ques-
tion or commenting on its importance (25%), ensuring 
the development or choice of outcome measures were 
important to patients (44%), assessing the burden of 
interventions or design of the intervention itself (44%) 
(table 3). In the study conduct phase, they participated as 
members of steering groups and research teams (38%), 
helped with participant recruitment or implementation 
(50%) and contributed to patient and public commu-
nication documents and materials (25%). They contrib-
uted to data analysis (6%) and the interpretation of study 
Table 1 Studies reporting some PPI in the research described: pre-implementation period
References Summary of PPI in the research Acknowledgement of PPI Funding*
Richards et al24 A patient coauthor of the journal article. The 
care management intervention was designed 
with and tested for acceptability with input 
from patients.
The public and patient advocate is an 
author on the byline of the article and their 
contributions to the manuscript are listed in the 
contributorship statement.
G
*G (Governmental)
PPI, patient and public involvement. 
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Table 2 Studies reporting some PPI in the research described: post-implementation period
Reference Summary of PPI in the research Acknowledgement of PPI Funding*
Enander et al32 Received input from patients from the BDD-NET pilot trial on 
the treatment material and this fed into the materials used in the 
main trial.
Trial participants were thanked and 
other individuals named and thanked 
for contributions, but it is unclear if they 
were patients.
G, T
Mant et al31 The study was discussed by a stroke survivor group who 
agreed that it was an important research question and that 
blood pressure was an important outcome for them. Patients 
were involved in developing recruitment plans and study design 
through representation on the Trial Steering Committee. Results 
will be disseminated to patient community through local and 
nationally organised stroke groups.
None. G
Smith et al26† During study design, a patient representative contributed to 
the grant application, study protocol and participant facing 
documentation. A patient representative was on the Trial Steering 
Committee, who helped to oversee progress of the trial and 
provided a patient’s perspective on aspects of trial conduct.
Patient representatives named and 
thanked.
G
Smith et al27† During study design, a patient representative contributed to 
the grant application, study protocol and participant facing 
documentation. A patient representative was on the Trial Steering 
Committee, who helped to oversee progress of the trial and 
provided a patient’s perspective on aspects of trial conduct.
Patient representatives named and 
thanked.
G
Andersson et al28 A community mobilisation protocol began with community 
discussion of baseline results. Former patients and their families 
were intimately involved in design and implementation of the 
intervention. In all intervention communities, brigadistas visited 
households and schools to teach mosquito control and cycle 
interruption. They recruited community leaders and added 
interventions as their community work advanced. They sought 
commonality of function by assuring the same protocol was 
used to generate community-led interventions. Patients and 
their families were also central to dissemination of the baseline 
information, which helped to motivate community involvement 
during and beyond the study.
None. G
Gilbody et al29 Patient and members of the public were involved in the design, 
management and conduct of the trial. They contributed 
to the design of trial materials and management oversight 
through membership of the trial steering committee. A user-
led organisation (Anxiety UK and Self-Help Services) acted 
as coapplicant (through its chief executive) and collaborator. 
Researcher assessed the burden of the trial interventions on 
patients. Plans to disseminate the results to trial participants 
and to seek PPI in the development of an appropriate method of 
dissemination.
Patient and public contributors thanked 
for their valuable input throughout the 
trial.
G
van der Aa et al30 Patients from low vision rehabilitation organisations were closely 
involved in the development and implementation of the stepped 
care programme based on two focus group meetings. Patients 
were not involved in determining study conduct, recruitment 
and design. The burden of the intervention and participation 
in the study, in general, was assessed by a panel of patient 
representatives, which was assigned by the funding agency. 
The burden of the intervention was not assessed as such by 
participating patients but satisfaction with the intervention was.
Patient representatives thanked for their 
support in developing the interventions 
as well as all study participants.
G, T
Ormerod et al25 Patients were involved in the design and conduct of this 
research. During the feasibility stage, priority of the research 
question, choice of outcome measures and methods of 
recruitment were informed by discussions with patients through 
a focus group session and two structured interviews. During the 
trial, a patient joined the independent trial steering committee. 
Members of the UK Dermatology Clinical Trials Network also 
identified this research as being a priority area for clinicians 
treating patients with pyoderma gangrenosum.
Those who contributed to the feasibility 
and pilot work for the subsequent trial 
were thanked.
G
Continued
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findings (13%), editing, revising and writing the manu-
script (19%) and directly in the development of dissemi-
nation materials (19%) to a lesser extent.
Direct PPI initiated by the research team in the 
dissemination phase was described in three papers in 
the post-implementation sample.28 29 39 In two of these 
three papers, patient coinvestigators or contributors were 
credited with helping to ensure the dissemination mate-
rials, and methods of dissemination were appropriate 
to reach beyond the research community to general 
Reference Summary of PPI in the research Acknowledgement of PPI Funding*
Coupland et al33 No patients were involved in setting the research question or 
the outcome measures, nor were they involved in the design or 
implementation of the study. No patients were asked to advise on 
interpretation or writing up of results. Patient representatives from 
the QResearch Advisory Board have advised on dissemination 
of studies using QResearch data, including the use of lay 
summaries describing the research and its results.
None. G
Hippisley-Cox 
and Coupland34
Patients were not involved in setting the research question, the 
outcome measures, the design or implementation of the study. 
Patient representatives from the QResearch Advisory Board have 
written the information for patients on the QResearch website 
about the use of the database for research. They have also 
advised on dissemination including the use of lay summaries 
describing the research and its results.
None. None
Bower et al37 Two survivors of Ebola virus disease were involved in developing 
the questionnaire and implementing the study. They were asked 
to advise on interpretation and writing up results.
‘Participants’ thanked for their time and 
thought given to the study. No specific 
or additional thanks are given to the 
survivors who were involved in the 
development of the questionnaire and 
the implementation of the study and 
advised on the interpretation and writing 
up of results.
G
Hippisley-Cox and  
Coupland35
Patients were not involved in setting the research question, the 
outcome measures, or the design or implementation of the study. 
Patient representatives from the QResearch Advisory Board have 
written the information for patients on the QResearch website 
about the use of the database for research. They have also 
advised on dissemination, including the use of lay summaries 
describing the research and its results.
None. None.
Turner et al36 Parents of young people with egg allergy were involved in the 
study design, development of study information leaflets and in 
setting the research question. Results disseminated through 
patient support organisations (Allergy UK and the Anaphylaxis 
Campaign) through electronic newsletters and social media.
Parents and young people who 
participated in the study were thanked 
but not those who contributed to the 
research.
G
Xian et al39 Incorporated input from patients throughout the entire research 
process. Results were reviewed with patient coinvestigators to 
obtain their perspectives and feedback to ensure that findings 
were presented in the most effective way beyond the research 
community to general populations.
Patient coinvestigators were credited for 
making high-value contributions to both 
the design and the implementation of the 
study. Three patient coinvestigators were 
made coauthors of the journal article.
G
Saadatmand et al38 Regular contact with members and representatives of the breast 
cancer patient organisations and charities made the relevance of 
the outcome measures of this study clear for patients in making 
informed decisions about treatment and screening. Patients 
were not further involved in the design of the study. Patients 
will be informed of the results of this study through information 
evenings and the websites of the named patient organisations 
and charities.
None. G
Amick et al40 A representative of the National (US) Board of Directors of the 
National Alliance on Mental Illness participated in the refinement 
of the research topic and the development of the preliminary 
research questions and review criteria. The research question 
and a draft version of the report were posted online for input from 
all members of the public, including patients and their advocates.
None. G
*I (Industry), G (Governmental), T (Trust), None (No external funding).
†These are two separate trials based on the same protocol but powered separately and published as two independent papers.
In the post-implementation period, authors were asked to describe how the results of the study will be disseminated to study participants.
PPI, patient and public involvement. 
Table 2 Continued 
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populations.29 39 In the third paper, patients and their 
families were described as "central to the dissemination of 
the baseline information, which helped to motivate community 
involvement during and beyond the study".28 In a further 
three papers, PPI in the dissemination phase was not 
explicitly reported but might be implied as patients or 
representatives were on the research steering committee 
and as such could have had the opportunity to contribute 
ideas to the format and method of dissemination.25–27 
In addition, there were three papers from the QRisk 
team reporting identical statements about some aspects 
of PPI in dissemination,33–35 but this PPI was specific to 
the QResearch database, not the individual published 
studies leaving uncertainty as to the extent of PPI within 
the individual studies. Three papers reported that results 
would be disseminated through patient and charitable 
organisations who may, in turn, involve patients in the 
dissemination process, but there was no reported PPI in 
dissemination conducted by the research team.31 36 38
Illustrative examples of PPI
We describe four examples from the post-implementation 
sample showing how researchers involved the patients 
and the public in several stages of research. These exam-
ples were chosen as they describe a range of approaches 
to involving patients at different stages in the research 
process. For more details of how other papers in the post-
implementation period reported PPI, see table 2.
In the UK’s Computerised cognitive behaviour therapy 
(cCBT) as treatment for depression in primary care 
(REEACT) trial, Gilbody et al29 involved patients and 
members of the public in multiple ways, including the 
design, management and conduct of the trial. Input in 
the design of trial materials was received from patients 
Table 3 Type of PPI explicitly reported before and after the introduction of a mandatory reporting policy 
Involvement type 
No. (%) 
Before (n=1) After (n=16)
Study design
  Contributions to the grant application and or study protocol 0/1 (0) 3/16 (19)
  Help to set the research question or commenting on its importance 0/1 (0) 4/16 (25)
  Ensuring the development of, or choice of, outcome measures were informed by patients’ 
priorities, experience and preferences
0/1 (0) 7/16 (44)
  Patient assessment of the burden of the intervention before the study commenced or 
involvement in designing the intervention (where applicable)*
1/1 (100) 4/9 (44)
Study conduct
  Involved in the study steering group or a member of the research team 1/1 (100) 6/16 (38)
  Recruitment and/or implementation of the research 0/1 (0) 8/16 (50)
  Patient/public communication materials for example, patient information sheets 0/1 (0) 4/16 (25)
Analysis
  Contributed to data analysis 0/1 (0) 1/16 (6)
  Interpretation of study findings 0/1 (0) 2/16 (13)
Drafting of the manuscript
  Contributions to editing, revising and or writing the manuscript 1/1 (100) 3/16 (19)
  Patients listed as coauthors 1/1 (100) 1/16 (6)
Dissemination
  Direct involvement of patients led by the research team including the development of materials 
for dissemination and choosing the most appropriate method of dissemination
0/1 (0) 3/16 (19)
  Indirect involvement through dissemination to patient charities, organisations and groups that 
may, in turn, involve patients in the process
0/1 (0) 3/16 (19)
  Patient representation informing the content of dissemination materials on a general advisory 
board for the use of the data used in research
0/1 (0) 3/16 (19)†
*The denominator only includes studies where there was an intervention that is, excludes systematic reviews, population based studies, 
secondary analyses and so on.
†This includes three papers from the QResearch team with identical statements about some aspects of PI in dissemination, but this PPI was 
specific to the QResearch database, not the individual published studies and it is not clear how much patients were involved in the individual 
studies reported.
Responses are not mutually exclusive. For example, if a patient  was on the steering group, this will be indicated in the relevant box and in the 
box about implementation of the research. However, not all those involved in study conduct were made members of steering groups. 
PPI, patient and public involvement. 
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who lived with depression and other common mental 
health problems. Trial management oversight included 
having patient members on the trial steering committee. 
A user-led organisation acted as grant coapplicant and as 
research collaborators. The authors reported that they 
carefully assessed the burden of the trial interventions 
on patients. Gilbody et al thank their patient and public 
contributors for their valuable input throughout the trial 
and plan to disseminate the results to trial participants 
and to seek PPI for developing the most appropriate 
dissemination method.
Andersson et al28 describe an RCT to develop commu-
nity mobilisation for dengue prevention in Nicaragua 
and Mexico. Protocol baseline results were discussed 
with patients, and they were intimately involved in design 
and implementation of the intervention. Local commu-
nity leaders became research team collaborators, and 
they invited community volunteers to receive training as 
organisers and educators. Once trained, they conducted 
home and school visits to show dwellers the evidence of 
larval/pupal infestation in water receptacles, to inform 
households and schools of the mosquito’s life cycle and to 
counsel on ways to interrupt the cycle. The research team 
worked with local leaders who added interventions as 
their community work advanced. They worked together 
by agreeing on a common protocol to generate commu-
nity-led interventions and to recommend participants for 
the intervention.
In the UK’s Comparison of the two most commonly 
used treatments for pyoderma gangrenosum (STOP 
GAP) trial, Ormerod  et al25 compared the two most 
commonly used treatments for pyoderma gangrenosum 
and involved patients in the trial design and conducting 
the study. Early on in the feasibility stage, patients priori-
tised the research question and selected the most relevant 
outcome measures. The methods of study recruitment 
were informed by discussions with patients in a focus 
group and two structured interviews. During the trial 
implementation phase, a patient joined the independent 
trial steering committee.
In the real world effectiveness of warfarin among isch-
emic stroke patients with atrial fibrillation: observational 
analysis from Patient-Centered Research into Outcomes 
Stroke Patients Prefer and Effectiveness Research 
(PROSPER) study, sponsored by the Patient-Centerd 
Outcomes Research Institute (PCORI), Xian et al39 
assessed the real-world effectiveness of warfarin among 
patients with ischaemic stroke with atrial fibrillation in the 
USA. They report partnering with patients throughout 
each stage of the research process. Patient coinvestiga-
tors worked iteratively with the research team to identify 
patient relevant research topics, healthcare priorities and 
meaningful outcomes for stroke survivors and then to 
develop patient-centred research questions. Patients also 
contributed to the statistical analysis plan and the interpre-
tation of the results to ensure that findings were dissemi-
nated in the most effective way to the general population. 
The value of including longitudinal functional outcomes, 
as prioritised by stroke survivors and stakeholders, was 
credited as a study strength. Patient coinvestigators were 
credited with making ‘high-value contributions to both the 
design and implementation of the study’. Three patient coin-
vestigators were made coauthors on the manuscript.
Acknowledgement and thanks for specific patient 
contributions to the research
This section describes how input from patients and the 
public was acknowledged in the papers. In 2 of the 17 
papers, patients were included as coauthors on the 
authorship byline.24 39 In six papers,25–27 29 30 39 patient 
contributors and advocates were thanked or acknowl-
edged for their contributions. In an additional paper, 
the value of the role of the patient contributions was 
mentioned in the main text, but no specific thanks were 
given in the acknowledgments.28 A further paper named 
and thanked people for helping with manuscript drafts, 
but it was not specified whether they were patients.32 In 
some manuscripts, organisations were named, however, 
individual collaborators were not and this made it diffi-
cult to appraise individual patient versus organisational 
choices that may or may not have been informed by 
patients. In 8 of 17 papers, patient contributors were 
not named, thanked or the value of their contributions 
acknowledged in general.
research funding
Governmental funding was accessed in all 17 studies 
reporting PI activity and all were led by academic prin-
cipal investigators. Two studies30 32 were partially funded 
by charitable trusts.
DIsCussIOn
Based on this analysis of published research papers in 
The BMJ, we found that a higher proportion of papers 
reported PPI activity after the introduction of a policy 
requiring this information be included, but there was a 
low level of reporting of PPI both before and after the 
introduction of this policy. This implies that the absence 
of information about PPI in research papers is not solely 
due to a lack of reporting requirments but a lack of PPI 
activity in practice or unwillingness to report unsuc-
cessful PPI. We took an inclusive approach and where any 
PPI was reported we counted it; but, some descriptions 
were of poor quality and lacked depth. However, some 
researchers who conducted the studies we sampled did 
find innovative ways of involving patients in all aspects of 
the research process. PPI in the early stages of research is 
recommended by organisations such as INVOLVE,41 Cana-
da’s Strategy for Patient-Oriented Research (SPOR),42 
and PCORI43 and widely considered to be best practice. 
We found examples of patients being involved from the 
earliest stages in grant applications and study design. 
They participated in steering groups, participant recruit-
ment, the identification and development of outcome 
measures, pilot testing platforms, conceiving interview 
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questions and implementation of the interventions. They 
were included in writing the manuscripts, revising drafts 
and in the dissemination of study results. Despite this key 
input, across 17 papers, only six acknowledged patients’ 
contributions and two included patient contributors as 
coauthors.
The implementation of PPI varies internationally. While 
authors in our study will have initiated their research 
prior to the introduction of The BMJ’s policy, ethical 
review boards and funding agencies in the UK have been 
requesting researchers to carry out and describe PPI for 
over 15 years. Recent data available on the extent of PPI in 
conducted research are sparse, but our findings are similar 
to earlier studies.16–18 While there has been some recent 
documentation on the rate of planned PPI in research 
submitted to the UK’s NRES (78% in 2012),15 research 
is not always conducted as planned, and it is important 
to evaluate the extent to which planned PPI gets imple-
mented in practice. The discrepancy between our findings 
and those of NRES can partially be explained by the fact 
that we included all study designs, research from outside 
the UK and that the cohort of studies under ethical review 
in 2012 may not have been published yet. We included 
papers describing systematic reviews, data linkage studies 
and secondary analyses. Some might argue that it is more 
difficult to involve patients in these study designs and that 
this has led to an underestimate of the rate of reporting. 
However, The Agency for Healthcare Research and Quality 
Evidence-based Practice Centres, the Institute of Medicine, the 
Cochrane Collaboration and others have recommended PPI 
when conducting systematic reviews, we used this justifi-
cation to include them.14 We recognise that many studies 
are secondary analyses of existing datasets or data linkage 
studies, and as such it may be harder to involve patients 
in the research process. However, there is still potential 
to include PPI in these types of studies and even in our 
study, we found examples where authors reported PPI in 
studies with these designs.33–35 38 40 For example, Amick 
et al40 conducted a systematic review and meta-analysis of 
antidepressants and cognitive behavioural therapies and 
involved a representative of the National (US) Board of 
Directors of the National Alliance on Mental Illness in 
the refinement of the research topic and the develop-
ment of the preliminary research questions and review 
criteria. The research question and a draft version of the 
report were posted online for input from all members of 
the public, including patients and their advocates. Saadat-
mand et al38 conducted a population-based study in the 
Netherlands where they relied on regular contact with 
patient-led and national breast cancer organisations to 
guide them in making the outcome measures clear for 
patients and members of the public to make informed 
choices about treatment and breast cancer screening and 
treatment.
Our study has several limitations. First, at the time of 
publication for papers in the pre-implementation sample 
in our study, there was no standardised format for reporting 
PPI information. This made it challenging to glean from 
the papers if and how patients were involved and as such 
we may have underestimated the rate of involvement. 
Our focus was on how PPI was reported in the published 
papers rather than on contacting the authors for further 
information or searching supporting material published 
elsewhere. We acknowledge that some studies may have 
involved patients in a range of ways and not reported this 
in the published paper. Authors have to balance the need 
to write succinctly with providing enough detail so that the 
research can be replicated. As editors and peer reviewers 
do not usually request PPI reporting, authors may not 
have considered including it and some may perceive 
it to have less value than other aspects of the research. 
Second, we only included one journal in our analysis and 
the results may not be generalisable to other biomedical 
research. However, it was The BMJ’s change in editorial 
policy around requirements for reporting PPI that made 
this before and after study possible. Third, it is possible 
that the frequency of reporting PPI in studies published 
by The BMJ is higher than current research practice as 
The BMJ has an active policy of reporting this involvement 
and promoting patient partnership.19 20 Finally, we cannot 
attribute causation to the implementation of this policy 
as the introduction of the policy itself may have attracted 
more research papers describing studies that included 
PPI.
There is substantial variation in the quality and content 
of reported PPI in the literature with limited method-
ological guidance for ways to initiate, sustain or report 
public involvement in research.44 Concannon et al45 
developed a set of seven questions to guide researchers 
in reporting PPI. In 2017, the first international guidance 
for reporting of PPI in health and social care research 
(GRIPP2 reporting checklist)46 was published with the 
aim of improving the quality, transparency and consis-
tency of the PPI evidence base and ensuring that prac-
tice is based on the best evidence. GRIPP2 is included 
in the Equator network (https://www. equator- network. 
org). Although it will take time to evaluate the influence 
of this reporting guideline in practice, it is a promising 
development. Clearer reporting of PPI could provide 
guidance for future research, set standards and improve 
best practice,47 reduce research ‘waste’, increase public 
goodwill and build a bank of viable ways to effectively 
involve patients and the public in research.10 We saw an 
increase in reporting of PPI after the introduction of a 
journal policy requiring this information be included. 
However, until requirements for PPI reporting are stan-
dardised and enforced by journals, funding institutions 
and sponsors, there is a danger that much research meth-
odology is likely to remain unreported and will contribute 
to research waste.2 10
COnClusIOns
PPI needs to be seen as an integral part of the research 
process and key to increasing its value. Best practice for 
reporting PPI should be supported and encouraged 
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as this serves to help others conduct and report more 
effective PPI. Funding organisations increasingly require 
researchers to involve patients and the public in their 
research,48 but closer monitoring of how planned PPI 
documented in grant applications transfers into practice 
is needed. Previous research has identified barriers to 
effective PPI,18 49–51 and these can be tackled by fostering 
collaboration, providing researchers with guidance and 
training on how to do PPI, and by providing adequate 
resources. Funders should ensure that dedicated provi-
sion is adequate to enable high-quality PPI and training 
and make reporting of PPI a mandatory requirement for 
continued funding. Researchers, patients and members of 
the public should share within their papers, and through 
dissemination materials what worked well and work in 
collaboration to bridge gaps and increase PPI aware-
ness and understanding. Journals should play a role in 
encouraging researchers to report PPI in a replicable way. 
Requiring a PPI statement within the Methods section of 
research papers should be adopted by other journals to 
help integrate meaningful PPI into the research culture.
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